The Use of Human Amniotic Membrane (hAM) as a Treatment Strategy of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis of the Literature
| Primer Autor |
Sacco, Roberto
|
| Co-autores |
Akintola, Oladapo
Sacco, Nicola
Acocella, Alessandro
Calasans-Maia, Monica Diuana
Maranzano, Massimo
Olate, Sergio
|
| Título |
The Use of Human Amniotic Membrane (hAM) as a Treatment Strategy of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis of the Literature
|
| Editorial |
MDPI
|
| Revista |
MEDICINA-LITHUANIA
|
| Lenguaje |
en
|
| Resumen |
Background and objectives: Although it is very uncommon, medication-induced osteonecrosis of the jaw (also known as MRONJ) can have serious consequences. Traditionally, this adverse event has been recognised in patients who were treated with bisphosphonate (BP) drugs. Nevertheless, in recent years, it has been established that individuals having treatment with various types of medications, such as a receptor activator of nuclear factor kappa-Beta ligand inhibitor (denosumab) and antiangiogenic agents, have had the same issue. The purpose of this research is to determine if the application of human amniotic membrane (hAM) may be used as a therapy for MRONJ. Material and Methods: A multi-source database (MEDLINE, EMBASE, AMED, and CENTRAL) systematic search was performed. The major objective of this study is to obtain an understanding of the efficacy of hAM when it is employed as a treatment modality for MRONJ. The protocol of this review was registered in the INPLASY register under the number NPLASY202330010. Results: The authors were able to include a total of five studies for the quality analysis, whereas for the quantity evaluation, only four studies were eligible. A total of 91 patients were considered for the investigation. After treatment with human amniotic membrane (hAM), a recurrence of osteonecrosis was observed in n = 6 cases (8.8%). The combined efficacy of surgical therapy and the use of hAM resulted in an overall success rate of 91.2%. Intraoperative complications were only documented in one article, and they were mostly caused by the positioning of the hAM, which led to wound breakdown at the surgical site. Conclusions: Based on the small amount of data and low-quality research included in this study, using human amniotic membranes to treat MRONJ might represent a feasible option. Nevertheless, further studies with a wider patient population are required to understand the long-term impacts.
|
| Fecha Publicación |
2023
|
| Tipo de Recurso |
artículo de revisión
|
| doi |
10.3390/medicina59050968
|
| Formato Recurso |
PDF
|
| Palabras Claves |
medication-related osteonecrosis of the jaw
skeletal-related events
human amniotic membrane
cancer
antiresorptive drugs
antiangiogenic drugs
|
| Ubicación del archivo | |
| Categoría OCDE |
Medicina general e interna
|
| Materias |
osteonecrosis de la mandíbula relacionada con medicamentos
eventos relacionados con el esqueleto
membrana amniótica humana
cáncer
fármacos antirresortivos
medicamentos antiangiogénicos
|
| Identificador del recurso (Mandatado-único) |
artículo de revisión
|
| Versión del recurso (Recomendado-único) |
versión publicada
|
| License |
CC BY 4.0
|
| Condición de la licencia (Recomendado-repetible) |
CC BY 4.0
|
| Derechos de acceso |
acceso abierto
|
| Access Rights |
acceso abierto
|
| Id de Web of Science |
WOS:000996544700001
|
| ISSN |
1010-660X
|
| Tipo de ruta |
verde# dorado
|
| Categoría WOS |
Medicina general e interna
|
cienciaabierta.ufro.cl
ciencia.abierta@ufrontera.cl